FULZOS 250 MG INJ PFS

About

FULZOS 250 MG INJ PFS contains Fulvestrant, an estrogen receptor antagonist that works by selectively binding to and degrading the estrogen receptor (ER). Unlike traditional selective estrogen receptor modulators (SERMs), Fulvestrant is a selective estrogen receptor downregulator (SERD), meaning it causes a significant reduction in the cellular levels of the ER protein. This mechanism makes it effective in treating hormone receptor-positive metastatic breast cancer in postmenopausal women.

By downregulating estrogen receptors, Fulvestrant prevents estrogen from binding to these receptors and stimulating cancer cell growth. This action is crucial in hormone-sensitive breast cancers where estrogen acts as a growth factor. It is often used in patients whose disease has progressed following anti-estrogen therapy, offering a distinct approach to endocrine therapy by completely blocking and degrading the estrogen receptor.

Uses

• Treatment of hormone receptor-positive metastatic breast cancer.
• Used in postmenopausal women.
• For disease progression after anti-estrogen therapy.
• Can be used alone or in combination with other targeted therapies.

Directions For Use

This medication is administered as an intramuscular injection by a healthcare professional. Follow your doctor's prescribed dosing schedule.

Benefits

• Effectively blocks estrogen receptor activity.
• Causes degradation of estrogen receptors.
• Offers a distinct mechanism from other endocrine therapies.
• Improves progression-free survival in eligible patients.
• Can be used after failure of other anti-estrogen treatments.
• Generally well-tolerated with a manageable side effect profile.

Side Effects

• Injection site pain
• Nausea
• Fatigue
• Headache
• Hot flashes
• Bone pain
• Arthralgia (joint pain)
• Back pain
• Vomiting
• Anorexia
• Peripheral edema
• Thromboembolic events (rare)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Fulvestrant can cause fetal harm. It is contraindicated in pregnant women. Effective contraception should be used during treatment and for one year after the last dose.
• Breastfeeding - It is unknown if Fulvestrant is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for one year after the last dose.
• Liver - Use with caution in patients with moderate to severe hepatic impairment. Dose adjustment may be necessary.
• Kidney - No dose adjustment is generally required for mild to moderate renal impairment. Use with caution in severe renal impairment.
• Lung - No specific lung-related precautions are generally needed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.